$FYB (+1,67%) Formycon has much more to offer, both Novartis/Sandoz and Fresenius are interested in the company according to stock market information. However, a takeover now would be much too early and bad for shareholders. Now already a biosimilar in the market, more will follow from 2024/2025 it will be really interesting. The 16% increase in the share price today was just the beginning. Price targets 500 - 1000 €. Thus a 10 bagger. Read the 60 page report "Formycon the next Tenbagger", available at Amazon.